Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Revive Therapeutics Ltd C.RVV

Alternate Symbol(s):  RVVTF

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is evaluating a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions or Long COVID. It also advancing the development of Psilocybin-based therapeutics through various programs. The Company's subsidiaries include Revive Therapeutics Inc. (Ontario), Revive Diagnostics Inc., and Psilocin Pharma Corp. (Ontario).


CSE:RVV - Post by User

Post by 1ottrunneron Jan 14, 2022 12:28pm
171 Views
Post# 34317486

Bucillamine's success is still priced in

Bucillamine's success is still priced in

Looking at the field of Psych stocks RVV still has 20-30% of it's value priced in from the success of the BUC trial.

With the new projected completed being the last day of Q1, I would enjoy revisiting 2021 promises but I waste of key presses, needless to say, NO TARGETS WERE MET in '21.

Pfizer is very close to getting the nod on their anti-viral pill in Canada and much of the world. RVV didn't bother recruiting in Canada, Turkey seemed a better venue I suppose. I wonder if the FDA agrees?

Recently someone posted an article which offered the stipend provided by RVV. It seems to me to be a very reasonable sum leaving me to believe MF raised said stipend recently, realizing that the stipend ensures trial envolvement and completion.

Its not like using the toe iron to ensure a sweet score on the back 9, is it MF?

Looks to be a wee bit of support at 29.5. 29 cents will trigger stop loses down to 24-26 cents. In my opinion that is about fair value with the latest trial update.

<< Previous
Bullboard Posts
Next >>